Brii Biosciences has stepped in to ease VBI Vaccines’ money problems. The Chinese biotech is handing VBI $15 million to strike a deal that will give it global license to a hepatitis B program—and an ongoing look at its partner’s financial situation.

Brii生物科学公司已介入解决VBI疫苗的资金问题。中国生物技术公司正在处理VBI 1500万美元，以达成一项协议，使其获得乙型肝炎项目的全球许可，并持续关注其合作伙伴的财务状况。

VBI agreed to collaborate with Brii to develop recombinant protein-based hepatitis B immunotherapy VBI-2601 in greater China in 2018 in return for a $4 million upfront payment and a $7 million equity investment. Three years later, the partners tweaked the deal to add another phase 2 combination trial of the candidate to the development plan..

VBI同意与Brii合作，于2018年在大中国开发基于重组蛋白的乙型肝炎免疫疗法VBI-2601，以换取400万美元的预付款和700万美元的股权投资。三年后，合作伙伴调整了交易，将候选人的另一个第二阶段组合试验添加到开发计划中。。

The latest change sees Brii pick up the rights to VBI-2601 in the rest of the world. Brii is paying $5 million upfront and committing up to $226 million in regulatory and sales milestones for the global license. The candidate, also known as BRII-179, is in phase 2 trials in China. Brii sees the asset as part of a functional cure and plans to study it in combination with other therapies..

Brii在世界其他地方获得了VBI-2601的权利。Brii正在支付500万美元的前期费用，并为全球许可证的监管和销售里程碑承诺高达2.26亿美元。该候选人，也称为BRII-179，正在中国进行2期试验。Brii将资产视为功能性治愈的一部分，并计划将其与其他疗法结合使用。。

As part of the amended deal, Brii is also paying $2 million upfront for rights to the FDA-approved PreHevbrio, a three-antigen vaccine for preventing hepatitis B, in most of Asia and making a $5 million advance payment for clinical and commercial supply of both VBI products. The final $3 million piece of the $15 million upfront is an equity investment in VBI..

作为修订协议的一部分，Brii还在亚洲大部分地区向FDA批准的用于预防乙型肝炎的三抗原疫苗PreHevbrio支付200万美元的权利，并为临床和商业供应支付500万美元。VBI产品。1500万美元前期的最后300万美元是VBI的股权投资。。

VBI filed to raise more money within minutes of disclosing the expanded Brii deal. The actions will shore up the financial position of a biotech that, like many of its peers, has faced mounting money worries in recent quarters. VBI burnt through more than $20 million over the first three months of the year, leaving it with $40.4 million in cash at the end of March.

VBI在披露扩大的Brii交易后的几分钟内提出筹集更多资金。这些行动将提升生物技术公司的财务状况，与其许多同行一样，近期该公司面临越来越多的资金担忧。VBI在今年的前三个月燃烧了超过2000万美元，到3月底留下了4040万美元的现金。

The biotech has cut spending, but cash remains tight..

生物技术公司减少了支出，但现金仍然紧张。。

Brii is keeping an eye on the situation with its partner. As part of the new deal, VBI has agreed to take certain steps when it has less than $50 million of consolidated cash on hand to fund ongoing operating activities. The biotech will provide Brii with a calculation “in reasonable detail” of its available operating cash, copies of materials it shares with its board and quarterly calls with Brii’s C-suite, as necessary..

Brii正在关注其合作伙伴的情况。作为新协议的一部分，VBI已同意在其现有合并现金少于5000万美元时采取某些措施为正在进行的运营活动提供资金。生物技术公司将根据需要为Brii提供其可用经营现金的“合理详细”计算，与其董事会共享的材料副本以及与Brii C-suite的季度通话。。